Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 57
- 试验地点
- 1
- 主要终点
- Change in ALT Index
研究概览
简要总结
Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
详细描述
Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness. The strongest fucoidan among all seaweed for inhibiting cancer cells is in Okinawa Japanese waters. For chemically speaking, the major components for fucoidan consisted of mainly fucose which is a kind of polysaccharide with strong biological activity. However, patients need to take actual fucoidan in order to reach the best effectiveness for inhibiting cancer cell.
Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients who are aged between 20-75 with non alcoholic fatty liver disease (NAFLD).
排除标准
- •Patients were allergic to seafood.
- •Patients who take Vitamin E or Pioglitazone.
研究组 & 干预措施
Fucoidan use
FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper)
干预措施: 275mg Oligo Fucoidan + 275mg HS Fucoxanthin (Other)
placebo pills
placebo capsule 6 per day (before breakfast and supper)
干预措施: placebo pills (Other)
结局指标
主要结局
Change in ALT Index
时间窗: 6 months
Measure the first month and the sixth-month change in the index which is ALT related to Liver inflammation.
Change in AST Index
时间窗: 6 months
Measure the first month and the sixth-month change in the index which is AST relate to Liver inflammation
Change in HbA1c
时间窗: 6 months
Measure the first month and the sixth-month change in the index which is HbA1c relate to Liver inflammation
次要结局
未报告次要终点